POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk Group
This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.